Status:
TERMINATED
A Pilot Study Evaluating Heart and Lung Metabolism in Pulmonary Hypertension Associated With Left Heart Disease
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Right ventricular (RV) failure is the leading cause of death in pulmonary arterial hypertension. (PAH) Right ventricular ejection fraction is one of the most important predictors of prognosis in heart...
Detailed Description
The hemodynamic definition of PH-LHD involves a mean pulmonary artery pressure (mPAP) \>25mm Hg at rest and pulmonary capillary wedge pressure (PCWP) of ≥15.The coexistence of mitral insufficiency is ...
Eligibility Criteria
Inclusion
- Patients must be able to provide their written informed consent to participate in the study after having received adequate previous information and prior to any study specific procedures.
- At least 18 years of age at the time of screening.
- Patients with PH secondary to left heart disease (known as group II PH) defined as a mean PAP\>25 mmHg and a PCWP of ≥15 mmHg.
Exclusion
- All other types of pulmonary hypertension including Dana Point Classification Group 1, 3, 5.
- Type II Diabetes mellitus requiring medical therapy
- Previous myocardial infarction within the 3 months prior to screening.
- Renal insufficiency (glomerular filtration rate \< 30 ml/min.
- ALT or AST \> 3times ULN and/or severe hepatic insufficiency.
- Contraindication to MRI imaging.
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02237378
Start Date
December 1 2014
End Date
August 1 2018
Last Update
August 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of OttawaHeart Institute
Ottawa, Ontario, Canada, K1Y4W7